SAN JOSE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial results for the second quarter ended June 30, 2025 and provided a corporate update.
“In the second quarter of 2025, we have announced a research collaboration with Chugai for two molecules with undisclosed targets,” said Talat Imran, Chief Executive Officer of Rani Therapeutics. “We believe this collaboration has the potential to transform into a long-term strategic partnership as we advance our pipeline of oral biologic therapies aimed at addressing the needs of patients with chronic diseases. Additionally, at ENDO 2025, we presented compelling preclinical data on our oral bispecific GLP-1/GLP-2 receptor agonist, RT-114. This data, demonstrating bioequivalence to subcutaneous injections in canines, highlights RT-114’s potential to revolutionize the obesity treatment landscape. Looking ahead to the second half of 2025, we remain focused on initiating a Phase 1 trial for RT-114 as a novel oral therapy for obesity.”
Second Quarter 2025 Highlights:
Near-Term Milestone Expectations:
Second Quarter 2025 Financial Results:
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, potential of Rani’s collaborations and its ability to transform such collaborations into a long-term strategic partnerships, including its collaboration with Chugai; ability to advance its pipeline of oral biologic therapies; the expected initiation of a Phase 1 trial of RT-114 in the second half of 2025, the potential of Rani’s collaboration with Chugai to transform into a long-term strategic partnership, our ability to advance our pipeline of oral biologic therapies, the potential of the RaniPill® platform to enable oral delivery of multiple obesity treatments and validation of such potential through preclinical data, the potential of the RaniPill® platform to offer more convenient and accessible therapeutic options, the potential for RT-114 to become a first-in-class, orally administered GLP-1/GLP-2 dual agonist for the treatment of obesity, the potential for RT-114 to revolutionize the obesity treatment landscape and the potential to become a novel oral therapy for the treatment of obesity, the sufficiency of Rani’s cash reserves, the timing and extent of its expenses, and future financial performance. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “confident,” “intend,” “potential,” “expect,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Rani’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Rani’s business in general and the other risks described in Rani’s filings with the Securities and Exchange Commission, including Rani’s annual report on Form 10-K for the year ended December 31, 2024, and subsequent filings and reports by Rani. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Rani undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investor Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
This email address is being protected from spambots. You need JavaScript enabled to view it.
RANI THERAPEUTICS HOLDINGS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except par value) | |||||||
June 30, | December 31, | ||||||
2025 | 2024 | ||||||
(Unaudited) | |||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 10,216 | $ | 3,762 | |||
Contract asset | — | 428 | |||||
Marketable securities | — | 23,877 | |||||
Prepaid expenses and other current assets | 857 | 1,677 | |||||
Total current assets | 11,073 | 29,744 | |||||
Property and equipment, net | 1,144 | 1,548 | |||||
Operating lease right-of-use asset | 4,388 | 5,096 | |||||
Other assets | 293 | 246 | |||||
Total assets | $ | 16,898 | $ | 36,634 | |||
Liabilities and Stockholders' Equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 1,798 | $ | 1,359 | |||
Accrued expenses and other current liabilities | 2,636 | 2,073 | |||||
Current portion of long-term debt | 15,000 | 15,000 | |||||
Current portion of operating lease liability | 1,189 | 1,459 | |||||
Total current liabilities | 20,623 | 19,891 | |||||
Long-term debt, less current portion | 2,229 | 9,613 | |||||
Operating lease liability, less current portion | 3,199 | 3,637 | |||||
Total liabilities | 26,051 | 33,141 | |||||
Stockholders' equity: | |||||||
Preferred stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of June 30, 2025 and December 31, 2024 | — | — | |||||
Class A common stock, $0.0001 par value - 800,000 shares authorized; 39,237 and 33,430 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 3 | 3 | |||||
Class B common stock, $0.0001 par value - 40,000 shares authorized; 23,970 and 23,972 issued and outstanding as of June 30, 2025 and December 31, 2024, respectively | 2 | 2 | |||||
Class C common stock, $0.0001 par value - 20,000 shares authorized; none issued and outstanding as of June 30, 2025 and December 31, 2024 | — | — | |||||
Additional paid-in capital | 111,280 | 104,889 | |||||
Accumulated other comprehensive gain | 3 | 5 | |||||
Accumulated deficit | (116,863 | ) | (102,907 | ) | |||
Total stockholders' (deficit)/equity attributable to Rani Therapeutics Holdings, Inc. | (5,575 | ) | 1,992 | ||||
Non-controlling interest | (3,578 | ) | 1,501 | ||||
Total stockholders' (deficit)/equity | (9,153 | ) | 3,493 | ||||
Total liabilities and stockholders' equity | $ | 16,898 | $ | 36,634 |
RANI THERAPEUTICS HOLDINGS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts) (Unaudited) | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2025 | 2024 | 2025 | 2024 | ||||||||||||
Contract revenue | $ | — | $ | — | $ | 172 | $ | — | |||||||
Operating expenses | |||||||||||||||
Research and development | 5,505 | 6,115 | 12,075 | 13,700 | |||||||||||
General and administrative | 5,000 | 6,409 | 10,615 | 12,857 | |||||||||||
Total operating expenses | $ | 10,505 | $ | 12,524 | $ | 22,690 | $ | 26,557 | |||||||
Loss from operations | (10,505 | ) | (12,524 | ) | (22,518 | ) | (26,557 | ) | |||||||
Other income (expense), net | |||||||||||||||
Interest income and other, net | 158 | 439 | 375 | 988 | |||||||||||
Interest expense and other, net | (877 | ) | (1,276 | ) | (1,819 | ) | (2,571 | ) | |||||||
Net loss | $ | (11,224 | ) | $ | (13,361 | ) | $ | (23,962 | ) | $ | (28,140 | ) | |||
Net loss attributable to non-controlling interest | (4,532 | ) | (6,556 | ) | (10,006 | ) | (13,852 | ) | |||||||
Net loss attributable to Rani Therapeutics Holdings, Inc. | $ | (6,692 | ) | $ | (6,805 | ) | $ | (13,956 | ) | $ | (14,288 | ) | |||
Net loss per Class A common share attributable to Rani Therapeutics Holdings, Inc., basic and diluted | $ | (0.18 | ) | $ | (0.26 | ) | $ | (0.40 | ) | $ | (0.55 | ) | |||
Weighted-average Class A common shares outstanding—basic and diluted | 36,542 | 26,324 | 34,999 | 26,179 |
Last Trade: | US$0.59 |
Daily Change: | -0.0076 -1.26 |
Daily Volume: | 566,170 |
Market Cap: | US$28.450M |
May 13, 2025 March 31, 2025 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load